Enalapril mitigates senescence and aging-related phenotypes in human cells and mice via pSmad1/5/9-driven antioxidative genes

Aging serves as a primary driver for numerous chronic conditions that impose significant healthcare burdens and complicate treatment due to multifactorial risk factors. Prior research has shown that cellular senescence contributes to the progressive decline of physiological integrity across diverse organ systems by halting the proliferation of essential cell populations. Identifying existing pharmaceuticals for repurposing offers a streamlined and cost-effective pathway to develop interventions targeting these complex age-related pathologies without the lengthy timelines of new drug discovery. While hypertension medications are frequently used in clinical settings, their broader impact on molecular aging markers and intracellular signaling remains only partially understood by the scientific community. Current therapeutic strategies often fail to address the underlying oxidative stress and reactive oxygen species production that accelerate biological decay at the cellular level. This absence of evidence motivated the investigation into how common antihypertensive agents might modulate specific intracellular signaling cascades to preserve cellular health and systemic function.

This investigation evaluates the efficacy of enalapril in mitigating senescence-associated phenotypes within human fetal lung fibroblasts and aged murine models to determine its potential as an anti-aging therapy. Researchers sought to determine if this specific angiotensin-converting enzyme inhibitor could influence the molecular pathways governing cellular longevity beyond its established role in blood pressure regulation. The study focused on identifying the specific intracellular mediators, particularly the Smad protein family, that translate pharmacological signals into robust antioxidative responses. Scientists aimed to observe the systemic effects of the drug on cognitive performance, memory retention, and renal health in older organisms to assess its impact on healthspan. The project explored the relationship between drug administration and the reduction of lipid deposits in metabolic tissues to understand its influence on aging-related metabolic shifts. Analysis targeted the potential for enalapril to serve as a dual-purpose agent for both cardiovascular management and the promotion of healthy aging in the elderly population.

Experiments used IMR90 human fetal lung fibroblasts to model cellular senescence under controlled laboratory conditions, allowing for precise observation of molecular changes. Aged mice served as the primary organismal model to assess the physiological impact of long-term drug exposure on complex biological systems. Investigators monitored the phosphorylation status of Smad1/5/9 proteins using specialized biochemical techniques to map the signal transduction cascade triggered by the medication. Quantitative assays measured the production of Reactive Oxygen Species (ROS) to evaluate changes in oxidative stress levels and the overall antioxidative capacity of the treated cells. Memory capacity was quantified through standardized behavioral testing protocols, while renal function was assessed via biochemical markers of kidney health and filtration efficiency. Histological analysis of various organ tissues allowed for the visualization and measurement of lipid accumulation within the subjects to determine metabolic improvements.

Enalapril administration significantly reduced cellular senescence markers in IMR90 cells by activating the pSmad1/5/9 signaling pathway as a central mediator. Activation of these mediators stimulated downstream genes responsible for cell cycle regulation and enhanced antioxidative defenses, which are essential for maintaining cellular homeostasis. Treated cells exhibited increased proliferation rates and a marked decrease in the generation of Reactive Oxygen Species (ROS), indicating a shift toward a more youthful metabolic state. Aged mice receiving the medication showed superior memory capacity compared to untreated control groups, suggesting a neuroprotective effect of the treatment. Renal function showed measurable improvement in the treated cohort, and the subjects displayed a significant reduction in systemic lipid accumulation across multiple tissues. These findings indicate that the drug bolsters physiological performance across multiple organ systems through molecular reprogramming of the pSmad1/5/9-driven antioxidative gene network.

The study establishes that enalapril functions as a potent modulator of aging-related phenotypes through specific intracellular signaling involving the pSmad1/5/9 pathway. Repurposing this antihypertensive medication provides a viable and efficient strategy for addressing the complex challenges of chronic age-related diseases and declining organ function. Future clinical applications might leverage these findings to promote healthy aging in populations already using angiotensin-converting enzyme inhibitors for cardiovascular health. The identification of pSmad1/5/9 as a central regulator of antioxidative genes opens new avenues for developing targeted anti-senescence therapies that mimic these effects. Enhancing antioxidative capacity through pharmacological means appears to be a pivotal factor in preserving organ function and cognitive performance during late-life stages. These results suggest that existing drugs can be optimized to extend the healthspan of aging individuals by targeting the fundamental mechanisms of cellular decay.